drugset / Trial / NCT06717880
A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer
Phase 1
Recruiting
260 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NaFactorialOpen-labelTreatment
Summary
A Phase 1 study of IBI363 in combination with Bevacizumab or Furuitinib in Subjects with Advanced Colorectal Cancer
Timeline
- Start
- 2023-07-28
- Primary completion
- 2025-07-31
- Completion
- 2026-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Furuitinib | Unknown | — | Oral |
| Subject | IBI363 | Protein / enzyme biologic | — | Intravenous |